/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).
/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA).
Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
This randomized clinical trial assesses the effect of adding panitumumab vs bevacizumab to standard first-line chemotherapy on overall survival among patients w
Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival
and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients
with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic
gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6
might represent a new first-line treatment in these patients.